TY - JOUR
T1 - Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer
AU - Tan, Marcus C.
AU - Al Mushawah, Fatema
AU - Gao, Feng
AU - Aft, Rebecca L.
AU - Gillanders, William E.
AU - Eberlein, Timothy J.
AU - Margenthaler, Julie A.
PY - 2009/10
Y1 - 2009/10
N2 - Background: The aim of the current study was to identify predictors of pathologic complete response (pCR) following neoadjuvant therapy. Methods: From 2000 to 2007, 518 breast cancer patients received neoadjuvant therapy. Data were compared using χ2 and Fisher's exact tests and multivariate analysis of variance, as appropriate. Results: Of 518 breast cancer patients receiving neoadjuvant therapy, 81 (16%) had pCR (77 of 456 [17%] with chemotherapy, 4 of 62 [6%] with endocrine therapy; P < .05). Four factors were associated with pCR: higher tumor grade (P = .015), lack of estrogen receptor (ER) and progesterone receptor (PR) expression (P < .0001), HER2/neu amplification (P = .025), and negative lymph node status (P < .0001). On multivariate analysis, ER and PR negativity, HER2/neu amplification, and negative lymph node status were found to significantly correlate with pCR. Conclusions: Patients with ER-negative and PR-negative and HER2/neu-amplified breast cancer phenotypes are more likely to experience pCR to neoadjuvant therapy. Although pCR is more frequently observed following neoadjuvant chemotherapy, it is rare following neoadjuvant endocrine therapy.
AB - Background: The aim of the current study was to identify predictors of pathologic complete response (pCR) following neoadjuvant therapy. Methods: From 2000 to 2007, 518 breast cancer patients received neoadjuvant therapy. Data were compared using χ2 and Fisher's exact tests and multivariate analysis of variance, as appropriate. Results: Of 518 breast cancer patients receiving neoadjuvant therapy, 81 (16%) had pCR (77 of 456 [17%] with chemotherapy, 4 of 62 [6%] with endocrine therapy; P < .05). Four factors were associated with pCR: higher tumor grade (P = .015), lack of estrogen receptor (ER) and progesterone receptor (PR) expression (P < .0001), HER2/neu amplification (P = .025), and negative lymph node status (P < .0001). On multivariate analysis, ER and PR negativity, HER2/neu amplification, and negative lymph node status were found to significantly correlate with pCR. Conclusions: Patients with ER-negative and PR-negative and HER2/neu-amplified breast cancer phenotypes are more likely to experience pCR to neoadjuvant therapy. Although pCR is more frequently observed following neoadjuvant chemotherapy, it is rare following neoadjuvant endocrine therapy.
KW - Breast cancer
KW - Neoadjuvant therapy
KW - Pathological response
UR - http://www.scopus.com/inward/record.url?scp=70349448551&partnerID=8YFLogxK
U2 - 10.1016/j.amjsurg.2009.06.004
DO - 10.1016/j.amjsurg.2009.06.004
M3 - Article
C2 - 19800460
AN - SCOPUS:70349448551
SN - 0002-9610
VL - 198
SP - 520
EP - 525
JO - American journal of surgery
JF - American journal of surgery
IS - 4
ER -